Scientist, Platform Enhancements
TCR² Therapeutics Inc. is an immuno-oncology company developing novel cancer therapies that unleash the full signaling power of complete T cell receptors (TCR). TCR² has developed a unique proprietary TRuC™ platform which can reprogram the natural TCR complex to recognize specific antigens found on tumors where they elicit rapid killing of cancer cells. The company has demonstrated activity against both hematological and solid tumor targets in preclinical models and believes its TRuC™-reprogrammed T cells will serve as the engine for important therapies. TCR² was founded by MPM Capital and has scientific operations in Cambridge, MA to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world.
The successful candidate will join the Innovation group utilizing in vitro cellular assays and immune cell profiling for the development and optimization of novel cell therapies for the treatment of cancer. The position represents an excellent growth and learning opportunity, working closely with experienced scientists in a fast-paced and highly collaborative environment.
Generate and test the function of lentivirally transduced T cells in cytokine release and killing assays.
Develop and implement assays to test the function of these cells in exhaustion and suppression assays.
Design and execute novel strategies to enhance the function of adoptive T cell therapies in the solid tumor microenvironment.
Identify and incorporate technologies that will expand our ability to assess the function of transduced T cells in multiple functional co-culture assays.
Lead research associates in executing experiments and in research meetings.
Present novel ideas and data in interdepartmental meetings.
Represent TCR² at external scientific meetings.
Ph.D. degree in immunology or molecular and cell biology. Candidates with 3+ years of post-doctoral training preferred.
Experience with primary cell and tumor cell culture.
Expertise with multicolor FACS and immune phenotyping required of human and murine cells is required.
Experience with chimeric antigen receptor (CAR) T cells, T cell activation, T cell-mediated cytotoxicity, T cell exhaustion is required.
Knowledge of immune suppressive mechanisms in the tumor microenvironment and T cell metabolism.
Prior experience with in vivo solid tumor models is desirable.
Familiarity with lentiviral or retroviral production and transduction of mammalian cells.
Proven track record of scientific accomplishments demonstrated by publications in high impact journals.
Outstanding critical thinking and organizational skills, leadership, and attention to detail.
Interested candidates should send their resume to email@example.com